Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › HER2-negative Breast Cancer

HER2-negative Breast Cancer

Part of Cancer

4 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for HER2-negative Breast Cancer

13 trials tracked for HER2-negative Breast Cancer: 1 in phase 3 or 4 and 1 with published results. The most-cited published study has 37 citations.

13Trials tracked
1Phase 3 & 4
0Recruiting
1With published results
Phase distribution
Phase 3 1 Phase 2 11 Phase 1 1
  1. Phase 3 Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer) Completed · 37 cited
  2. Phase 2 Nab-Paclitaxel and Bevacizumab Followed By Bevacizumab and Erlotinib in Metastatic Breast Cancer Completed
  3. Phase 2 Efficacy and Safety of BGB-290 in the Treatment of Metastatic HER2-Negative Breast Cancer Patients With BRCA Mutation in China Completed
  4. Phase 2 Comparison of Neoadjuvant Chemotherapy With Weekly Paclitaxel or Eribulin Followed by A/C in Women With Locally Advanced HER2-Negative Breast Cancer Completed
  5. Phase 2 Carboplatin and Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IIB-IIIC Breast Cancer Completed
  6. Phase 2 Trial of Eribulin/Cyclophosphamide or Docetaxel/Cyclophosphamide as Neoadjuvant Therapy in Locally Advanced HER2-Negative Breast Cancer Completed
Show 7 more trials
  1. Phase 2 Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer Completed
  2. Phase 2 Carboplatin+Nab-paclitaxel, Plus Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting Completed
  3. Phase 2 A Study of Mirdametinib on Its Own or in Combination With Fulvestrant in People With Solid Tumor Cancer Completed
  4. Phase 2 A Study to Investigate the Biological Effects of AZD9833 in Women With ER-positive, HER2 Negative Primary Breast Cancer Completed
  5. Phase 2 Umbrella Trial of Subtype-Targeted Therapies in ER+/HER2- Breast Cancer Completed
  6. Phase 2 A Dose Escalation/Expansion Study of Oral OP-1250 in Subjects With Advanced and/or Metastatic HR+, HER2- Breast Cancer Completed
  7. Phase 1 A Multi-Center, Open-Label Study of Fruquintinib in Solid Tumors and Colorectal, and Breast Cancers Completed

Showing the 13 most-cited and recently-updated of 13 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

HER2-negative Breast Cancer: what the trials found

In the management of HER2-negative breast cancer, nab-Paclitaxel demonstrated statistically significant improvements in progression-free survival (PFS) based on investigator assessment, with Kaplan-Meier estimates reaching 5.5, 8.3, and 6.0 months respectively (p=0.0183) 3. Clinical response rates for this intervention were reported at 39.3%, 73.4%, and 43.9% 3.

Paclitaxel has been evaluated in this patient population, with a reported 2-year overall survival (OS) rate of 88.5% and 92.6% 10. Additional data confirms the use of Paclitaxel in clinical settings for this condition 11.

Recent results — preliminary, needs further review

  • Alpelisib showed a reduction in the percentage change of Ki67 across multiple cohorts (-0.64; -0.68; -0.63; -0.46) 2.
  • OP-1250 is currently being evaluated in Phase 2 trials 1.

For the clinician treating this condition

  • Nab-Paclitaxel shows statistically significant improvements in progression-free survival (PFS) compared to standard measures 3.
  • Paclitaxel demonstrates high 2-year overall survival rates in HER2-negative breast cancer patients 10.

AI synthesis of 5 cited trials, updated Jun 29, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Datopotamab deruxtecan showed no overall survival benefit versus investigator's choice chemotherapy in metastatic HR-positive breast cancer.
OB/GYN & Women's Health RCT
Datopotamab deruxtecan showed no overall survival benefit versus investigator's choice chemotherapy in metastatic HR-positive breast cancer. Datopotamab deruxtecan extends life for advanced breast cancer patients
This Phase III randomized controlled trial evaluated datopotamab deruxtecan versus investigator's choice chemotherapy in patients with inope…
New drug datopotamab deruxtecan helps advanced breast cancer patients live longer and stay disease-free
Jun 4, 2026
Gedatolisib plus fulvestrant with or without palbociclib improved progression-free survival versus fulvestrant monotherapy in advanced breast cancer
Oncology RCT
Gedatolisib plus fulvestrant with or without palbociclib improved progression-free survival versus fulvestrant monotherapy in advanced breast cancer New Drug Combo Slashes Breast Cancer Progression Risk by 75%
This phase III randomized trial evaluated gedatolisib plus fulvestrant with or without palbociclib in patients with hormone receptor-positiv…
For patients with tough-to-treat advanced breast cancer, a new three-drug combination nearly quadrupled the time before the cancer started g…
Apr 20, 2026
Phase 1 trial of oral ASTX727 plus talazoparib in previously treated triple-negative metastatic breast cancer patients
Oncology Phase I
Phase 1 trial of oral ASTX727 plus talazoparib in previously treated triple-negative metastatic breast cancer patients New Drug Combo Stops Breast Cancer Growth
This Phase 1 study enrolled 34 evaluable patients with previously treated triple-negative, hormone-resistant, or HER2-negative metastatic br…
This new combination may help some patients keep their cancer stable for months when other options have run out.
Apr 16, 2026
RAD51-foci Score Predicts Olaparib Efficacy in Advanced HER2-negative Breast Cancer
OB/GYN & Women's Health Phase II
RAD51-foci Score Predicts Olaparib Efficacy in Advanced HER2-negative Breast Cancer Could a Simple Test Help Tailor Breast Cancer Treatment?
Phase II study shows RAD51-foci score predicts olaparib response in BRCA1/2, PALB2, RAD51C/D mutated breast cancer. Study enrolled 65 patien…
A new test may help doctors choose the right drug sooner for women with advanced breast cancer who have specific genetic mutations.
CT.gov Mar 27, 2026

Research across Cancer

Related studies from across the Cancer family.

Meridian Sinew Tuina significantly reduces upper limb circumference and pain in breast cancer-related lymphedema
Oncology Meta-analysis
Meridian Sinew Tuina significantly reduces upper limb circumference and pain in breast cancer-related lymphedema Meridian Sinew Tuina May Help Manage Breast Cancer Lymphedema
This meta-analysis evaluated the impact of Meridian Sinew Tuina on patients with breast cancer-related lymphedema. The analysis found signif…
A specialized deep tissue massage technique called Meridian Sinew Tuina shows promise in reducing swelling and pain for those with breast ca…
Sep 9, 2026
Statins reduce recurrence risk 23% and mortality in 267,913 HR+ breast cancer patients with HR 0.77
Oncology Meta-analysis
Statins reduce recurrence risk 23% and mortality in 267,913 HR+ breast cancer patients with HR 0.77 Statins lower recurrence and death risk in hormone receptor-positive breast cancer
This systematic review and meta-analysis evaluated statin use versus non-use in 267,913 patients with hormone receptor-positive breast cance…
A massive analysis of over 267,000 patients shows statins reduce recurrence and death risk in hormone receptor-positive breast cancer.
Frontiers Jun 3, 2026
Immunotherapy improves complete response but lacks overall response benefit in HR+ breast cancer
Oncology Meta-analysis
Immunotherapy improves complete response but lacks overall response benefit in HR+ breast cancer Immunotherapy shows mixed results for hormone-positive breast cancer patients
This systematic review and meta-analysis evaluated immunotherapy in patients with hormone receptor-positive and human epidermal growth facto…
A large analysis found immunotherapy did not improve overall survival but did increase side effects for hormone-positive breast cancer patie…
Jun 1, 2026
Trastuzumab deruxtecan improves PFS vs chemotherapy in HR-positive, HER2-low breast cancer
OB/GYN & Women's Health RCT
Trastuzumab deruxtecan improves PFS vs chemotherapy in HR-positive, HER2-low breast cancer Trial shows T-DXd beats chemo for breast cancer
In a phase 3 RCT of 866 patients with HR-positive, HER2-low/-ultralow metastatic breast cancer after endocrine therapy, trastuzumab deruxtec…
A new drug, T-DXd, helps people with a common type of advanced breast cancer live longer without their disease getting worse.
Jun 1, 2026
Lymphovenous anastomosis improves quality of life in breast cancer-related lymphedema
OB/GYN & Women's Health Meta-analysis
Lymphovenous anastomosis improves quality of life in breast cancer-related lymphedema Lymphedema surgery improves quality of life in breast cancer survivors
This meta-analysis of observational studies found that therapeutic lymphovenous anastomosis (LVA) significantly improves quality of life in …
A new analysis finds that lymphovenous anastomosis significantly boosts quality of life for breast cancer survivors with lymphedema, especia…
Jun 1, 2026
Weight reduction ranked highest for limb volume, while VR-based training ranked highest for pain in breast cancer-related lymphedema
Oncology Meta-analysis
Weight reduction ranked highest for limb volume, while VR-based training ranked highest for pain in breast cancer-related lymphedema Weight loss and virtual reality rank highest for breast cancer swelling and pain relief
This network meta-analysis of 754 patients evaluated non-pharmacological therapies for breast cancer-related lymphedema. Weight reduction ra…
Weight loss and virtual reality training ranked best for reducing arm swelling and pain in breast cancer patients, though other therapies al…
Frontiers May 30, 2026
Healthcare professionals need updated guidance on managing breast cancer-related lymphedema effectively today
Oncology Sys. Review
Healthcare professionals need updated guidance on managing breast cancer-related lymphedema effectively today Review updates care for breast cancer-related lymphedema
This narrative review aims to apprise healthcare professionals with the latest understanding of optimal care and counseling patients regardi…
A new review summarizes the latest understanding of breast cancer-related lymphedema to help healthcare professionals counsel patients.
Frontiers May 23, 2026
Review covers capecitabine and trastuzumab emtansine for triple-negative and HER2-positive breast cancer
Oncology Sys. Review
Review covers capecitabine and trastuzumab emtansine for triple-negative and HER2-positive breast cancer Breast Cancer Chemo Is Getting Smarter and More Effective
This narrative review examines emerging therapies for women with breast cancer, including triple-negative and HER2-positive disease. The aut…
New blood tests and tumor markers are helping doctors choose the right chemo for breast cancer, reducing resistance and improving survival.
Frontiers May 8, 2026
FDA Approves Enhertu (fam-trastuzumab deruxtecan-nxki) for Multiple HER2-Positive and HER2-Low Cancers
Oncology FDA Approval
FDA Approves Enhertu (fam-trastuzumab deruxtecan-nxki) for Multiple HER2-Positive and HER2-Low Cancers FDA approves Enhertu for several types of HER2 positive cancers.
FDA approved Enhertu for several indications including HER2-positive metastatic breast cancer, HER2-low and HER2-ultralow breast cancer, HER…
The FDA has approved Enhertu for multiple cancers, including breast, lung, stomach, and other solid tumors that have a specific protein call…
FDA May 2, 2026
Protocol for randomized controlled trial of TEAS pretreatment for breast cancer-related lymphedema
Oncology RCT
Protocol for randomized controlled trial of TEAS pretreatment for breast cancer-related lymphedema New electrical therapy may stop breast cancer swelling before surgery starts
This document outlines a randomized controlled trial protocol evaluating transcutaneous electrical acupoint stimulation pretreatment in brea…
A new electrical therapy might stop arm swelling before breast cancer surgery begins
Frontiers Apr 29, 2026
Taxane-Based and Long-Course Chemotherapy Linked to Higher Breast Cancer-Related Lymphedema Risk
Oncology Cohort
Taxane-Based and Long-Course Chemotherapy Linked to Higher Breast Cancer-Related Lymphedema Risk New Data Links Chemo Drugs to Arm Swelling in Breast Cancer
In a retrospective cohort of 201 breast cancer patients at Guangzhou Red Cross Hospital, taxane-based regimens, long-course chemotherapy, an…
Breast cancer patients on certain chemotherapy drugs face a higher risk of developing arm swelling after treatment ends.
Frontiers Apr 27, 2026
CDK4/6i plus AI or fulvestrant shows similar clinical benefit in HR+ HER2- MBC
Drug Pipeline Cohort
CDK4/6i plus AI or fulvestrant shows similar clinical benefit in HR+ HER2- MBC Two drugs linked to longer survival than palbociclib in breast cancer
This retrospective single-center analysis of 341 patients with HR+/HER2− MBC found that palbociclib, abemaciclib, and dalpiciclib combined w…
In a real-world analysis, two CDK4/6 inhibitors showed longer survival times than palbociclib for metastatic breast cancer patients.
Frontiers Apr 24, 2026

Questions about HER2-negative Breast Cancer

Is the combination of ASTX727 and talazoparib being tested for HER2-negative Breast Cancer?

A phase 1 trial is testing the combination of ASTX727 and talazoparib for triple-negative metastatic breast cancer and hormone-resistant breast cancer.

Full answer →